Ongoing Research Aims to Use Bispecific Antibodies in Earlier Settings and Novel Combinations in Myeloma
Joshua Richter, MD, provides an overview of the current state of bispecific antibodies in multiple myeloma, discusses ongoing investigations of these agents, and expands on their unique toxicities and the need for proactive management.